According to Lumos Pharma's latest financial reports the company's current EPS (TTM) is -4,25 โฌ. In 2022 the company made an earnings per share (EPS) of -4,17 โฌ a decrease over its 2021 EPS that were of -3,26 โฌ.
Year | EPS | Change |
---|---|---|
2023 (TTM) | -4,43 โฌ | 6.07% |
2022 | -4,17 โฌ | 27.98% |
2021 | -3,26 โฌ | 305.62% |
2020 | -0,80 โฌ | -90.26% |
2019 | -8,26 โฌ | -29.48% |
2018 | -11,71 โฌ | -38.72% |
2017 | -19,10 โฌ | -20.07% |
2016 | -23,90 โฌ | 111.51% |
2015 | -11,30 โฌ | -137.77% |
2014 | 29,92 โฌ | -396.77% |
2013 | -10,08 โฌ | 10.71% |
2012 | -9,11 โฌ | 6.4% |
2011 | -8,56 โฌ |